Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study
Scott M.J., Xiang, H., Hart, D.P., Palmer, B., Collins, P.W., Stephensen, D., Sima, C.S. and Hay, C.R.M. 2018. Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study. Haemophilia. https://doi.org/10.1111/hae.13616
|Authors||Scott M.J., Xiang, H., Hart, D.P., Palmer, B., Collins, P.W., Stephensen, D., Sima, C.S. and Hay, C.R.M.|
Introduction: The THUNDER study provides an analysis of treatment patterns and outcomes in UK patients with severe or moderate haemophilia A (SHA/MHA) in 2015.
Methods: Patients with SHA or MHA registered with the UK National Haemophilia Database (NHD) were segregated by severity, inhibitor status and age. Haemophilia joint health score (HJHS) was derived from NHD records and treatment regimen and annualized bleed/joint‐bleed rate (ABR/AJBR) from Haemtrack (HT) in HT‐compliant patients.
Results: We report 1810 patients with SHA and 864 with MHA. Prophylaxis was used in 94.9% (n = 130/137) of HT‐compliant children <12 years with SHA, falling to 74.1% (n = 123/166) aged ≥40 years. Median ABR increased with age (1.0, IQR 0.0‐5.0, <12 years; 3.0 IQR, 1.0‐8.0, ≥40 years). Inhibitors were present in 159 (8.8%) SHA and 34 (3.9%) MHA. Median ABR increased from 2.0 (<12 years) to 21.(≥40 years) in SHA inhibitor patients using prophylaxis. Prophylaxis was used by 68.8% of HT‐compliant MHA patients (n = 106) (median FVIII baseline 0.01 IU/mL) associated with a median (IQR) ABR of 3.0 (1.0‐7.0). Median HJHS (n = 453) increased with age in SHA and MHA. Median (IQR) HJHS was higher in SHA inhibitor (17.0, 0.0‐64.5) than non‐ or past inhibitor patients (7.0, 0.0‐23.0).
Conclusions: Increasing ABR with age persists despite current prophylaxis regimens.SHA and MHA had similar ABR/AJBR and HJHS, leading to a suspicion that a subgroup of MHA may be relatively undertreated. More intensive prophylaxis may improve outcomes, but this requires further study.
|Keywords||Annualized bleed rate; FVIII inhibitors; Haemophilia A, ; Haemophilia joint health score; Prophylaxis|
|Digital Object Identifier (DOI)||https://doi.org/10.1111/hae.13616|
|Online||08 Nov 2018|
|Publication process dates|
|Accepted||08 Sep 2018|
|Deposited||31 Mar 2022|
|Accepted author manuscript|
3views this month
0downloads this month